17,261 trials
Extensive Stage Small Cell Lung Cancer · Recurrent Small Cell Lung Cancer
Primary: Objective Response Rates (Complete and Partial) Evaluated Using RECIST Criteria — 2 participants
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage III Renal Cell Cancer
Primary: Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II) — 48.6 percent
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Healthy Volunteers
Primary: Area Under the Curve of Plasma Naproxen From 0 to t — 67763.0; 69427.9 min×μg/mL
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Coronary Artery Disease
Primary: Clinical Procedural Success — 100 percentage of participants
Hepatitis C
Primary: Virological Response at Week 28 (W28VR) — 61; 60 participants — p=0.855
Leukemia
Primary: Proportion of Patients Achieving Hematologic and Molecular Complete Remission (CR) After Induction Therapy — 91 percentage of analyzable subjects
Complicated Intra-abdominal Infection
Primary: Clinical Response to TP-434 and Ertapenem in the Microbiologically Evaluable (ME) Population at the Test-of-Cure Visit — 39; 41; 24; 3 participants
Schizophrenia
Primary: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (Double Blind Phase) — -9.76; -18.73; -16.19; -18.25 Units on a scale — p=0.2846
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter · Recurrent Bladder Cancer · Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Number of Paricipants With Tumour Response Defined as Partial or Complete Response Per the RECIST 1.0 Criteria — 0 participants
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Cure Rate
Primary: 28-day Cure Rate — 63.67 Percentage of participants
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary · Recurrent Salivary Gland Cancer
Primary: Progression Free Survival (PFS) — 3; 3.2 months
Advanced Gastric Cancer
Primary: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) — 3 participants